Original Article

Efficacy of oxaliplatin combined with Tiji’ao and recombinant human endostatin injection in treatment of late gastric cancer and the effects on serum tumor markers

Huanzhen Zhang¹, Yunlong Wang², Ruiyan Fang³

Departments of ¹Blood Transfusion, ²Radiotherapy, Central Hospital of Linyi City, Yishui County, Linyi City, Shandong Province, China; ³Radiation Chamber, Central Hospital of Linyi City, Yishui County, Linyi City, Shandong Province, China

Received January 7, 2018; Accepted March 17, 2018; Epub April 15, 2018; Published April 30, 2018

Abstract: Objective: To investigate the efficacy of oxaliplatin combined with Tiji’ao (Tegafur + gimeracil + oteracil) and recombinant human endostatin injection in treatment of late gastric cancer and the effects on serum tumor markers. Methods: In total, 120 patients with late gastric cancer hospitalized and treated in Central Hospital of Linyi City from June 2014 to December 2015 were selected and randomly divided into the observation group and the control group, with 60 patients in each group. The control group was given chemotherapy with Tiji’ao + oxaliplatin, while the observation group given recombinant human endostatin injection in addition to those of the control group. Three serum tumor markers (carcinoembryonic antigen and carbohydrate antigens (CA125 and CA199)) were detected before and during treatment, and the clinical efficacy, adverse reactions, and survival times were compared between the two groups. Results: The control group had a higher clinical response rate than the observation group (88.3% vs. 68.3%, P=0.03). The main adverse reactions of the two groups were bone marrow depression and gastrointestinal reactions, of which the incidences were insignificantly changed (P=0.19). Both groups had significantly decreased expression levels of serum tumor markers, and the observation group had significantly greater decreasing extents than the control group (P=0.01, P=0.01, P=0.02). The median survival times of the observation group and control group were (15.03±2.37) months and (14.41±2.74) months, respectively, and the difference was statistically insignificant (P=0.21). Conclusion: Oxaliplatin combined with Tiji’ao and recombinant human endostatin injection in treatment of late gastric cancer has excellent clinical efficacy, without increasing chemotherapy toxicity, and consequently is worthy of clinical application.

Keywords: Gastric cancer, recombinant human endostatin injection, chemotherapy

Introduction

Gastric cancer is one of the common malignant tumors of digestive system, with an increasing incidence year by year. But by the time of discovery, most cases are late and have missed the opportunity of surgery, and only can be treated with conservative treatments, among which, chemotherapy is the the most important. At present, the American National Comprehensive Cancer Network guide recommends chemotherapy with platinum combined with fluorouracil, but it is intolerable, with severe gastrointestinal reactions. Therefore, it is especially important to search for a safe and effective chemotherapy regimen [1]. Tiji’ao is a newly invented oral drug to treat gastric cancer, which has definite clinical efficacy and is easy to use. Oxaliplatin is a drug of platinum, with fewer adverse reactions than the other platinum chemotherapeutics [2, 3]. Recombinant human endostatin is a vascular endothelium inhibitor that can prevent vascular endothelial cell migration and promote cell apoptosis, and consequently can inhibit the angiogenesis, has synergistic effects on chemotherapeutics, and has been used for various tumors including lung cancer [4-7]. Regardless of the chemotherapy regimen used, the survival time of late gastric cancer is still hovering around 9-11 months and in very few cases, the survival time is longer than 1 year, and then reaches a huge bottleneck [8]. Hence, it is critical to actively look for new treatment modalities. In this study, we
investigated the efficacy of Tiji’ao combined with oxaliplatin and recombinant human endostatin in treatment of late gastric cancer, which was excellent. The details were reported below.

**Materials and methods**

**General data**

This was a prospective study. In total, 120 patients with advanced gastric carcinoma hospitalized and treated in Central Hospital of Linyi City from June 2014 to December 2015 were selected, including 71 males and 49 females, aged 42-68 years, average: (52.08±11.07) years and the course of disease was 7 years (with a mean duration of 4.27±0.59 years).

### Table 1. Comparison of general data between the two groups

<table>
<thead>
<tr>
<th></th>
<th>Observation group</th>
<th>Control group</th>
<th>t/χ²</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case number</td>
<td>60</td>
<td>60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>31/29</td>
<td>40/20</td>
<td>2.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Age</td>
<td>49.73±12.32</td>
<td>51.06±20.06</td>
<td>4.06</td>
<td>0.16</td>
</tr>
<tr>
<td>Course of disease</td>
<td>4.15±0.15</td>
<td>4.41±1.42</td>
<td>0.29</td>
<td></td>
</tr>
<tr>
<td>Site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric body</td>
<td>16</td>
<td>14</td>
<td>1.64</td>
<td>0.13</td>
</tr>
<tr>
<td>Gastric fundus</td>
<td>13</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pylorus</td>
<td>20</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardia</td>
<td>11</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNM staging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td>37</td>
<td>35</td>
<td>2.52</td>
<td>0.09</td>
</tr>
<tr>
<td>Stage IV</td>
<td>23</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pathological type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poorly differentiated adenocarcinoma</td>
<td>30</td>
<td>33</td>
<td>4.43</td>
<td>0.17</td>
</tr>
<tr>
<td>Moderately differentiated adenocarcinoma</td>
<td>20</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signet-ring cell carcinoma</td>
<td>10</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal cavity</td>
<td>20</td>
<td>21</td>
<td>2.51</td>
<td>0.21</td>
</tr>
<tr>
<td>Left supraclavicular part</td>
<td>22</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>8</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>10</td>
<td>10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 2. Comparison of clinical efficacy between the two groups (n, %)

<table>
<thead>
<tr>
<th>Group</th>
<th>Cases</th>
<th>Complete remission</th>
<th>Partial remission</th>
<th>Stable disease</th>
<th>Progressive disease</th>
<th>Response rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation group</td>
<td>60</td>
<td>14</td>
<td>39</td>
<td>5</td>
<td>2</td>
<td>53 (88.3)</td>
</tr>
<tr>
<td>Control group</td>
<td>60</td>
<td>10</td>
<td>31</td>
<td>14</td>
<td>5</td>
<td>41 (68.3)</td>
</tr>
</tbody>
</table>

χ² 8.15
P 0.03

Inclusion criteria: (1) All the patients were diagnosed with stage II gastric cancer, which was confirmed by pathological examination; (2) All the patients were diagnosed with advanced gastric carcinoma (referring to lymphatic metastasis, penetration depth, and nearby organ invasion), which was confirmed by clinical staging, gastroscopy, B ultrasonography, and CT; (3) All the patients were treated with no other chemotherapeutics; (4) The liver and kidney functions, lung function, and ECG were all normal, and all the patients had no contraindications to chemotherapy [3]; (5) All the patients were cooperative in treatment, and had no history of drug allergy.

Exclusion criteria: (1) Patients complicated by tumors of other tissues or organs; (2) Patients who were uncooperative in the treatment, and those with incomplete follow-up data; (3) Patients complicated by severe nervous or mental disorders.
The lesions were at gastric body, fundus, pylorus, cardia, in 30, 26, 44 and 20 cases, respectively. The cancer degrees were staged as stage III (n=72) and stage IV (n=48) by TNM staging method. Pathological types: Poorly differentiated adenocarcinoma (n=63), moderately differentiated adenocarcinoma (n=40), and signet ring cell carcinoma (n=17). Distant metastasis: metastasis to celiac lymph nodes (n=41), to left supraclavicular lymph nodes (n=42), to liver (n=17), and to lung (n=20). The selected subjects were randomly divided into the observation group and the control group according to the admission date, with 60 patients in each group. The two groups had insignificantly differences in sites, TNM stages, pathological types, metastatic sites, etc. (P>0.05). See Table 1. All the selected subjects signed informed consent, and the study was approved by the Medical Ethics Committee of Central Hospital of Linyi City.

**Treatment methods**

The control group was given Tiji’ao Capsules (Qilu Pharmaceutical Co., Ltd) 40 mg/m² p.o B.i.d (once after breakfast and the other after supper) for 2 continuous weeks; and oxaliplatin (Jiangsu Hengrui Medicine Co., Ltd.) 130 mg/m² i.v gtt within 2 h for at least 2 cycles (3 weeks a cycle). In addition to those of the control group, the observation group was given recombinant human endostatin injection (Shandong Simoere Maidejin Biological Pharmaceutical Co., Ltd.) 15 mg i.v gtt for 2 weeks, which was repeated after a 1-week interval, for at least 2 cycles (3 weeks a cycle). Before chemotherapy, the two groups were given routine hydration, diuresis, oral dexamethasone, anti-emesis, fluid infusion, and other supportive and symptomatic treatments. In the chemotherapy period, raw, cold, and hard dietary stimulation were avoided, routine blood test and hepatic and renal functions were re-tested regularly, and drugs used for increasing in white cells were given when necessary.

**Detection of tumor markers carcinoembryonic antigen (CEA) and S100**

Before and after chemotherapy of both groups, 10 mL of peripheral venous blood was drawn and centrifuged at 1,500 r/min for 10 min, and the supernatant was taken and stored at -80°C for test. The expression of tumor markers CEA and S100 were detected by enzyme linked immunosorbent assay on a detection kit bought from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd. strictly complying with the procedures described in the package insert.

**Clinical efficacy judgment and follow-up**

Short-term efficacy was judged according to WHO solid tumor efficacy criteria as follows [5]. Complete remission (CR): All the lesions disappeared and the minor axis of the any pathological lymph nodes (regardless of targeted lesion) should be <10 mm. Partial remission (PR): With the sum of critical radii as reference, the sum of all targeted lesion radii was decreased by at least 30%. Stable disease: With the minimum of the sum of the studied targeted lesion radii as reference, patients failed to meet the remission criteria and progressive criteria. Progressive disease: The number or size of the lesions was obviously increased compared with before. Overall response rate=(CR + PR)/total case number *100%. Long-term efficacy was analyzed based on median survival time. The follow-up time started from the end of chemotherapy to death, loss to follow up, or end of follow up, to January 2016.
Efficacy of oxaliplatin with Tiji’ao and recombinant human endostatin injection

Adverse reactions

Adverse reactions were classified complying with the National Cancer Institute - Common Toxicity Criteria as grade 0-IV [9]. Grade 0: There were no or just mild symptoms, requiring no treatment; grade I: the symptoms were indicative of minimum, local, or non-invasive treatment, and age-related instrumental activities of daily living were limited; grade II: the symptoms were not life-threatening, but prolonged the length of stay and resulted in disability, and self-care activities of daily living were limited; grade III: the symptoms were life-threatening and required emergent treatment; and grade IV: death.

Statistical methods

The test data were treated by SPSS13.0 statistical software. Numeration data were expressed in %, and inter-group comparison was tested by χ² test; and measurement data are expressed as (X ± sd), and inter-group comparison was tested by t test. Survival time was analyzed based on Kaplan-Meier survival curve. The difference in survival between the two groups was analyzed by Log-rank test. When P<0.05, the difference was statistically significant.

Results

Comparison of clinical efficacy between the two groups

The observation group had a significantly higher overall response rate than the control group (53/60, 88.3% vs. 41/60, 68.3%; χ²=8.15, P=0.03). The details are shown in Table 2.

Comparison of adverse reactions between the two groups

Adverse reactions of the two groups were mainly digestive tract reactions and bone marrow depression, including leucopenia, nausea, vomiting, and decreased food appetite. The incidence of leucopenia of the observation group was 78.3% (47/60), among which, that of grade III-IV was only 3.3% (2/60); while the incidence of leucopenia of the control group was 88.3% (53/60), among which, that of grade III-IV was 6.7% (4/60); and the difference was statistically insignificant (P=0.19). Other differences in adverse reaction incidence were all statistically insignificant (P=0.24). The details are shown in Table 3.

Comparisons of tumor markers before and after chemotherapy between the two groups

After 4 cycles of chemotherapy, both the observation group and control group had significantly decreased CEA, CA125 and CA199 levels com-
Efficacy of oxaliplatin with Tiji’ao and recombinant human endostatin injection

pared with those before chemotherapy (t=10.03, P=0.02; t=11.38, P=0.02; t=9.85, P=0.02); and after chemotherapy, the two groups had significantly different tumor markers (CEA, CA125, CA199) with a statistical significance (t=7.06, P=0.03; t=7.31, P=0.03; t=6.95, P=0.04). The details are shown in Figure 1.

Survival analysis

All the subjects of this study were followed up for more than 2 years. The follow-up was ended on January 1, 2016. Among the 120 patients, 113 completed the follow-up, and 3 of the observation group and 4 of the control group were lost, with a loss rate of 5.8%. The data on the lost population was treated as truncated. In total, 8 patients died of gastric cancer recurrence. The median survival times of the observation group and control group were (15.03 ±2.37) months and (14.41±2.74) months, respectively, and the difference was statistically insignificant (t=6.46, P=0.21). The details are shown in Figure 2.

Discussion

Gastric cancer is one of the common malignant tumors of digestive system, with an increasing incidence year by year following the aging of the population in our country. But by the time of discovery, most cases are complicated by penetration of surrounding tissues and organs, and have missed the best opportunity of surgery. As revealed by domestic and abroad clinical trials in recent years, systemic chemotherapy in patients with late gastric cancer can effectively relieve the clinical symptoms, improve the quality of life, prolong survival time, and inhibit tumor penetration [10, 11]. Systemic chemotherapy has become the first choice to treat late gastric cancer.

At present, there are many chemotherapeutics for late gastric cancer, such as fluorouracil, cisplatin, anthracyclines, and mitomycin, but the clinical efficacy of these chemotherapeutics is uncertain, with a low availability. In recent years, following the development of new chemotherapeutics and renovation of chemotherapy regimens, the chemotherapy efficacy is greatly elevated. Oxaliplatin is a third-generation platinum chemotherapeutic. It can combine with DNA to form a compound to hinder DNA transcription, with stronger effects, rapi-
Efficacy of oxaliplatin with Tiji’ao and recombinant human endostatin injection

combined with chemotherapeutics to treat non-small-cell lung carcinoma, with excellent clinical efficacy [16]. We observed the clinical efficacy of recombinant human endostatin combined with chemotherapeutics in treatment of late gastric cancer, and discovered that the response rate was up to 80.0% and the median survival time was 15.03 months, which were significantly higher than single chemotherapy group (P<0.05). Tumor markers are important indexes reflecting the presence and malignancy degree of tumors, and is an important reference index for chemotherapy efficacy. The results of our study suggested Recombinant human endostatin could effectively decrease the serum levels of each tumor marker (CEA, CA125 and CA199) in patients with late gastric cancer, and further confirmed the effects of recombinant human endostatin of inhibiting the growth and development of tumors.

When adding new drugs to the routine chemotherapy, the following two issues should be considered: the toxicity of the drug itself and aggravating the adverse reactions of chemotherapy or not. It is confirmed by generous drug clinical trials that the main adverse reactions of recombinant human endostatin were in the cardiovascular system, such as myocardial ischemia, but they are slight, most can be recovered to normal after symptomatic treatments, and result in no death [18-20]. Our study results discovered treatment with recombinant human endostatin combined with chemotherapeutics had basically accordant kind, frequency, and severity degree of adverse events with those of singe use, and suggested it had good safety. We know recombinant human endostatin is a vasodepressor, and may cause bleeding easily, while gastric cancer is a malignant tumor of a hollow organ; thus, whether using recombinant human endostatin will increase the chance of gastric bleeding or not needs large-sample clinical investigations.

To sum up, oxaliplatin combined with Tiji’ao and recombinant human endostatin injection in treatment of late gastric cancer has excellent clinical efficacy, can decrease tumor marker levels, without increasing the incidence of adverse events, and consequently is worthy of clinical application.

Disclosure of conflict of interest

None.

Address correspondence to: Ruiyan Fang, Radiation Chamber, Central Hospital of Linyi City, No.17 Health Road, Yishui County, Linyi City 276400, Shandong Province, China. Tel: +86-0539-2263414; E-mail: fangruiyan105@126.com

References


Efficacy of oxaliplatin with Tiji’ao and recombinant human endostatin injection


